インターベンショナルカーディオロジーおよび末梢血管デバイス市場：製品タイプ、用途、エンドユーザー、地域別、2024年～2031年

インターベンショナルカーディオロジーおよび末梢血管デバイス市場の評価-2024-2031

心血管疾患の世界の増加により、低侵襲治療への需要が高まっています。特に先進国では高齢化が進み、心臓や血管疾患の発生率が高くなっているため、高度な医療介入が必要となっており、市場開拓は2024年に240億8,000万米ドルを突破し、2031年には436億4,000万米ドルに達する見込みです。

さらに、薬剤溶出性ステント、生体吸収性血管足場、カテーテルベースの新技術の開発など、現在進行中の技術進歩により、これらの処置の有効性と安全性が向上しています。医療費の増加と、心血管系疾患の早期発見・治療の利点に対する意識の高まりが市場成長の原動力となっており、2024年から2031年にかけてCAGR約8.51％で成長すると予想されます。

インターベンショナルカーディオロジーおよび末梢血管デバイス市場定義/概要

インターベンショナルカーディオロジーおよび末梢血管デバイスは、心臓の血管や末梢動脈に影響を及ぼす疾患の診断や治療に使用される特殊な医療器具やインプラントです。ステント、カテーテル、バルーン、ガイドワイヤーなどは、冠動脈疾患、末梢動脈疾患、その他の血管障害を治療するための低侵襲手技で使用される器具のひとつです。これらの器具の使用は、開腹手術を必要とせずに血流を回復させ、心臓発作のリスクを低下させ、患者の予後を改善するために不可欠です。技術の進歩、世界人口の高齢化、心血管疾患の有病率の増加により、この市場の将来は有望です。生体吸収性ステントや薬剤溶出技術の開発などの技術革新の継続と新興国市場におけるヘルスケアインフラの拡大が、これらの機器の世界の成長と普及を促進すると予想されます。

低侵襲治療に対する需要の高まりがインターベンショナルカーディオロジーおよび末梢血管デバイス市場を促進する？

低侵襲手技に対する需要の高まりは、インターベンショナルカーディオロジーおよび末梢血管デバイス市場を促進すると予想されます。従来の開腹手術と比較して、ステント、バルーン、カテーテルの使用などの低侵襲手技は、回復時間の短縮、入院期間の短縮、合併症発生率の低下など、数多くの利点をもたらします。心血管系疾患が依然として世界の死因の上位を占める中、ヘルスケア業界は患者の予後を改善するために、より侵襲性の低い先進的な手技への依存度を高めています。こうした手技は、慢性心疾患が多い先進国の高齢者の間で特に人気があります。

2024年6月、メドトロニックは、末梢動脈疾患の治療に使用される新しい低侵襲バルーンカテーテルのFDA承認を取得しました。この器具は、周辺組織への影響を最小限に抑えながら正確な治療を可能にするもので、血管治療における非侵襲的ソリューションの拡大傾向を浮き彫りにしています。2024年5月、ボストン・サイエンティフィックは最新の薬剤溶出ステントも発表しました。このステントは、冠動脈の再狭窄を減少させ、開心術に代わるより安全で効果的な治療法を提供することを目的としています。

2024年3月、欧州医薬品庁（EMA）は、救命技術への迅速なアクセスという重要なニーズを認識し、低侵襲性心血管系機器の承認プロセスを迅速化するための新たな規制イニシアチブを発表しました。これらの政策は、より多くの企業がインターベンショナル・カーディオロジー分野で技術革新を行うことを奨励することを意図しています。全体として、世界中のヘルスケアシステムが患者の安全性と費用対効果を優先しているため、低侵襲手技に対する需要がインターベンショナルカーディオロジーおよび末梢血管デバイス市場の成長を促進すると予想されます。

先進医療機器の高コストがインターベンショナルカーディオロジーおよび末梢血管デバイス市場の成長を阻害するか？

先端医療機器のコストが高いことが、インターベンショナルカーディオロジーおよび末梢血管デバイス市場の成長を制限しています。薬剤溶出ステント、生体吸収性血管スカフォールド、先進カテーテルなどの最先端技術を含むこれらの医療機器は、広範な研究開発および規制当局の承認プロセスが必要なため、高額になることが多いです。このため、特に医療予算が限られ、患者の自己負担額が法外に高い発展途上国では、これらの医療機器へのアクセスが悪くなる可能性があります。その結果、コストが重要視される市場では、こうした先端機器の導入が遅れる可能性があります。

高コストはヘルスケア提供者にも影響を及ぼし、医療提供者は最先端技術を使用するメリットと医療機関の財政的制約とを天秤にかけなければならないです。特に公的医療制度や保険償還率の低い地域では、病院や診療所が予算の制約に直面し、高価な新型機器への投資能力が制限される可能性があります。その結果、地理的な位置や社会経済的な地位によって患者が受けられる医療の質に格差が生じ、市場全体の成長を阻害する可能性があります。

さらに、先端医療機器のコストが高いことは、業界の技術革新を阻害する可能性があります。企業は、コスト面の懸念によって製品市場が制約されると考えれば、新技術の開発に投資することをためらうかもしれないです。その結果、画期的なイノベーションよりも、既存機器の漸進的な改良に重点が置かれることになりかねないです。長期的には、先端機器の高額なコストが、最も効果的で革新的な治療法の普及を阻む障壁となり、インターベンショナルカーディオロジーおよび末梢血管デバイス市場の成長の可能性を制限する可能性があります。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主な調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 インターベンショナルカーディオロジーおよび末梢血管デバイス市場：製品タイプ別

• 冠動脈ステント
• 薬剤溶出ステント
• ベアメタルステント
• 生体吸収性ステント
• カテーテル
• ガイドワイヤー
• バルーン
• アテレクトミーデバイス
• 慢性完全閉塞（CTO）デバイス
• プラーク修正デバイス
• 塞栓防止装置
• その他

第5章 インターベンショナルカーディオロジーおよび末梢血管デバイス市場：用途別

• 冠動脈疾患
• 末梢動脈疾患
• その他

第6章 インターベンショナルカーディオロジーおよび末梢血管デバイス市場：エンドユーザー別

• 病院
• 外来手術センター
• その他

第7章 地域分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第8章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第9章 競合情勢

• 主要企業
• 市場シェア分析

第10章 企業プロファイル

• Abbott Laboratories
• B. Braun Melsungen AG
• Biotronik SE & Co. KG
• Boston Scientific Corporation
• C.R. Bard（BD）
• Cardinal Health Inc.
• Cook Medical
• Koninklijke Philips N.V.
• Medtronic plc
• Teleflex Inc.
• Terumo Group
• W. L. Gore & Associates Inc.

第11章 市場の展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第12章 付録

• 略語リスト
• 出典と参考文献

Interventional Cardiology and Peripheral Vascular Devices Market Valuation - 2024-2031

The rising global prevalence of cardiovascular diseases is driving up demand for minimally invasive procedures. The aging population, particularly in developed countries, is contributing to a higher incidence of heart and vascular diseases, necessitating advanced medical interventions evolving the market growth surpassing USD 24.08 Billion in 2024 and reachUSD 43.64 Billion by 2031.

Furthermore, ongoing technological advancements, such as the development of drug-eluting stents, bioresorbable vascular scaffolds, and novel catheter-based technologies, improve the efficacy and safety of these procedures. Increasing healthcare spending and growing awareness of the benefits of early detection and treatment of cardiovascular diseases help to drive market growth is expected to grow at aCAGR of about 8.51% from 2024 to 2031.

Interventional Cardiology and Peripheral Vascular Devices Market: Definition/ Overview

Interventional cardiology and peripheral vascular devices are specialized medical instruments and implants used to diagnose and treat conditions affecting the heart's blood vessels and peripheral arteries. Stents, catheters, balloons, and guidewires are among the devices used in minimally invasive procedures to treat coronary artery disease, peripheral artery disease, and other vascular disorders. The use of these devices is critical for restoring blood flow, lowering the risk of heart attack, and improving patient outcomes without the need for open surgery. The future of this market looks promising, thanks to technological advancements, an aging global population, and an increasing prevalence of cardiovascular diseases. Continued innovation, such as the development of bioresorbable stents and drug-eluting technologies, while expanding healthcare infrastructure in emerging markets are expected to drive the growth and adoption of these devices globally.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Will Rising Demand for Minimally Invasive Procedures Propel the Interventional Cardiology And Peripheral Vascular Devices Market?

The growing demand for minimally invasive procedures is expected to propel the interventional cardiology and peripheral vascular devices market. In comparison to traditional open surgeries, minimally invasive techniques, such as the use of stents, balloons, and catheters, provide numerous advantages, including shorter recovery times, shorter hospital stays, and lower complication rates. As cardiovascular diseases remain a leading cause of death worldwide, the healthcare industry is increasingly relying on advanced, less invasive procedures to improve patient outcomes. These techniques are particularly popular among the elderly in developed countries, where chronic heart disease is common.

In June 2024, Medtronic received FDA approval for a new minimally invasive balloon catheter used to treat peripheral artery disease. This device enables precise treatment with minimal impact on surrounding tissue, highlighting the growing trend of non-invasive solutions in vascular care. In May 2024, Boston Scientific also introduced its latest drug-eluting stent, which is intended to reduce restenosis in coronary arteries while providing a safer and more effective alternative to open-heart surgery.

In March 2024, the European Medicines Agency (EMA) announced new regulatory initiatives to speed up the approval process for minimally invasive cardiovascular devices, recognizing the critical need for quicker access to life-saving technologies. These policies are intended to encourage more companies to innovate in the field of interventional cardiology. Overall, as healthcare systems around the world prioritize patient safety and cost-effectiveness, the demand for minimally invasive procedures is expected to fuel growth in the interventional cardiology and peripheral vascular devices market.

Will High Cost of Advanced Medical Devices Hinder the Growth of the Interventional Cardiology and Peripheral Vascular Devices Market?

The high cost of advanced medical devices limits the growth of the interventional cardiology and peripheral vascular devices market. These devices, which include cutting-edge technologies such as drug-eluting stents, bioresorbable vascular scaffolds, and advanced catheters, are often expensive due to the extensive research, development, and regulatory approval processes required. This can make these devices less accessible, especially in developing countries where healthcare budgets are limited and patients' out-of-pocket costs are prohibitively high. As a result, adoption of these advanced devices may be slower in markets where cost is an important consideration.

The high cost also affects healthcare providers, who must weigh the benefits of using cutting-edge technologies against their institutions' financial constraints. Hospitals and clinics may face budgetary constraints that limit their ability to invest in costly new devices, particularly in public healthcare systems or in areas with lower insurance reimbursement rates. This can result in disparities in the quality of care available to patients based on their geographical location or socioeconomic status, potentially impeding overall market growth.

Furthermore, the high cost of advanced medical devices can stifle innovation in the industry. Companies may be hesitant to invest in the development of new technologies if they believe the market for these products is constrained by cost concerns. This could result in an emphasis on incremental improvements to existing devices rather than ground-breaking innovations. In the long run, the high cost of advanced devices may act as a barrier to widespread adoption of the most effective and innovative treatments, limiting the growth potential of the interventional cardiology and peripheral vascular devices market.

Category-Wise Acumens

Will Rising Demand for Drug-Eluting Stents (DES) Drive the Interventional Cardiology And Peripheral Vascular Devices Market?

The increasing demand for drug-eluting stents (DES) is expected to drive significant growth in the interventional cardiology and peripheral vascular devices market. DES are becoming dominant due to their effectiveness in preventing restenosis, which is the re-narrowing of arteries following stent placement. These stents are coated with medication that is slowly released to reduce inflammation and the likelihood of artery reblockage, making them a better option than bare-metal stents. The benefits of DES, such as improved patient outcomes and fewer repeat procedures, are consistent with the growing global emphasis on effective and long-lasting cardiovascular treatments.

In June 2024, the European Medicines Agency (EMA) issued new guidelines to expedite the approval process for advanced cardiovascular devices, including DES. This move is intended to improve patients' access to innovative treatments throughout Europe. In May 2024 In the United States, the Food and Drug Administration (FDA) announced an initiative to increase funding for clinical trials examining the efficacy of DES in diverse populations, demonstrating a commitment to advancing the development and accessibility of these critical devices. These regulatory actions highlight the importance of DES in the cardiovascular market and support its continued expansion.

Chronic Total Occlusion (CTO) Devices are the fastest-growing segment of the market. The increasing prevalence of complex coronary artery disease, as well as technological advancements that improve the success rates of CTO procedures, are driving this growth. CTO devices are intended to treat long-term blockages in coronary arteries that have proven resistant to conventional treatments. The development of more effective and less invasive CTO devices is accelerating their adoption, reflecting a larger trend toward better solutions for difficult vascular conditions.

Will Rising Prevalence of Coronary Artery Diseases Dominate the Interventional Cardiology And Peripheral Vascular Devices Market?

Rising incidences of coronary artery disease (CAD) are expected to initiate its dominance in the interventional cardiology and peripheral vascular devices market. CAD is one of the most common cardiovascular diseases in the world, owing primarily to rising risk factors such as aging populations, unhealthy lifestyles, and high obesity and diabetes rates. As CAD remains a leading cause of morbidity and mortality, there is a steady and growing demand for advanced medical devices designed to treat it. These devices, which include drug-eluting stents, coronary balloons, and advanced catheter systems, are critical for managing and alleviating the effects of CAD. The consistently high demand for these technologies demonstrates their market dominance.

In June 2024, the US Centers for Disease Control and Prevention (CDC) announced a new initiative aimed at lowering the incidence of cardiovascular disease by improving access to innovative interventional technologies. This initiative includes funding for hospitals to acquire advanced CAD treatment devices as well as enhanced healthcare provider training. Furthermore, in May 2024, the European Society of Cardiology (ESC) updated its guidelines to emphasize the use of cutting-edge interventional devices in CAD management, reflecting a growing recognition of the importance of these technologies in improving patient outcomes. These developments highlight the importance of CAD in driving market trends, as well as the ongoing focus on improving treatment options for this common condition.

Peripheral Artery Disease (PAD) is the most rapidly growing application segment. PAD's rapid growth is attributed to an aging population, rising diabetes rates, and increased awareness of the condition. PAD, which affects blood flow to the limbs, is becoming more common as lifestyle risk factors increase. Advances in treatment technologies, such as new-generation balloon catheters and atherectomy devices designed specifically for PAD, are driving market growth in this area. The emphasis on improving patient outcomes and expanding treatment options for PAD is fueling this segment's rapid growth.

Country/Region-wise

Will Advanced Healthcare Infrastructure in North America Drive the Interventional Cardiology And Peripheral Vascular Devices Market?

The advanced healthcare infrastructure in North America is a major driver of the interventional cardiology and peripheral vascular devices market. This region, with its well-established healthcare systems, cutting-edge medical facilities, and high healthcare expenditure, is an ideal environment for the adoption of advanced medical technologies. The presence of leading healthcare institutions and research centers promotes innovation and early adoption of new cardiovascular devices, which are essential for treating heart disease and peripheral vascular conditions. As cardiovascular diseases continue to be the leading cause of death in North America, the demand for these devices grows, driven by the need for effective and minimally invasive therapies.

The United States government has also played an important role in this development. In April 2024, the Centers for Medicare and Medicaid Services (CMS) implemented new reimbursement policies for advanced cardiovascular procedures, making these life-saving interventions more accessible to a larger patient population. This policy shift is expected to increase the adoption of interventional cardiology and peripheral vascular devices in North America, bolstering the region's global market leadership. North America's strong healthcare system, government support, and continuous innovation position it as a market leader.

Will Increasing Incidence of Cardiovascular Conditions in Asia-Pacific Propel the Interventional Cardiology and Peripheral Vascular Devices Market?

The rising prevalence of cardiovascular diseases in Asia-Pacific is expected to drive rapid growth of this region in the interventional cardiology and peripheral vascular devices market. The prevalence of cardiovascular diseases in Asia-Pacific is rapidly increasing, owing to factors such as aging populations, unhealthy diets, sedentary lifestyles, and rising hypertension and diabetes rates. This increase in cardiovascular conditions is driving up demand for advanced medical devices that can effectively treat and manage these diseases, particularly through minimally invasive procedures. As a result, Asia-Pacific's interventional cardiology and peripheral vascular device markets are expected to grow significantly.

In June 2024, Medtronic announced that it had expanded its operations in India and China, two of Asia-Pacific's largest markets, to increase the availability of its most recent stents and balloon catheters. This move aims to meet the growing demand for cardiovascular treatments in these countries, where the prevalence of heart disease is rapidly increasing. Similarly, in July 2024, Boston Scientific launched a new series of drug-eluting stents in the Asia-Pacific market, specifically designed to meet the region's unique patient needs. These developments emphasize the importance of the Asia-Pacific market for major medical device manufacturers, as well as the region's growing role in the global healthcare landscape.

Asia-Pacific countries are taking proactive measures to address the rising cardiovascular disease burden. For instance, in May 2024, the Chinese government announced a new initiative to improve heart disease prevention and treatment using advanced medical technologies. This initiative includes financial incentives for hospitals to purchase cutting-edge interventional cardiology devices, as well as training programs for healthcare professionals to improve their skills in using these devices. Similarly, in April 2024, the Indian government announced that it would expand its National Programme for the Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS), with a focus on increasing access to life-saving cardiovascular interventions. These government efforts are expected to increase the adoption of interventional cardiology and peripheral vascular devices in Asia-Pacific, driving significant market growth.

Competitive Landscape

The competitive landscape of the interventional cardiology and peripheral vascular devices market is characterized by a mix of emerging players, regional manufacturers, and specialized companies focusing on niche segments. These competitors are leveraging innovative technologies and strategic partnerships to gain market share, particularly in areas like drug-eluting stents, atherectomy devices, and bioresorbable vascular scaffolds. Companies are also increasingly focusing on developing cost-effective solutions to cater to price-sensitive markets, particularly in emerging economies. Additionally, the market sees continuous product launches and FDA approvals, with smaller firms often introducing novel devices that address specific clinical needs, thus intensifying competition.

Some of the prominent players operating in the interventional cardiology and peripheral vascular devices market include:

Abbott Laboratories

Braun Melsungen AG

Biotronik SE & Co. KG

Boston Scientific Corporation

R. Bard (BD)

Cardinal Health, Inc.

Cook Medical, Koninklijke Philips N.V.

Medtronic plc

Teleflex, Inc.

Terumo Group

L. Gore & Associates, Inc.

Latest Developments

In May 2024, Abbott introduced a new bioresorbable stent in Europe, marking a significant step forward in interventional cardiology. The stent is intended to dissolve gradually, minimizing the long-term complications associated with traditional metal stents.

In April 2024, Terumo introduced a new peripheral guidewire in Japan with the goal of improving intervention precision in complex vascular cases. This product launch is part of Terumo's strategy to broaden its offerings in the peripheral vascular device market.

In January 2024, BD received CE mark approval for its most recent vascular access device, which includes advanced antimicrobial technology to reduce infection risks during interventional procedures. This development demonstrates BD's commitment to innovation in the peripheral vascular space.

In February 2024, Cardinal Health introduced a new line of vascular closure devices in the United States, designed to reduce bleeding complications following interventional procedures. This product line is intended for hospitals seeking cost-effective and efficient closure solutions.

In March 2022, Philips announced the acquisition of a leading vascular imaging software firm, expanding its image-guided therapy portfolio. This acquisition is expected to help Philips improve its capabilities in both interventional cardiology and peripheral vascular interventions.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Interventional Cardiology And Peripheral Vascular Devices Market, By Product Type

• Coronary Stents
• Drug-Eluting Stents
• Bare-Metal Stents
• Bioabsorbable Stents
• Catheters
• Guidewires
• Balloons
• Atherectomy Devices
• Chronic Total Occlusion (CTO) Devices
• Plaque Modification Devices
• Embolic Protection Devices
• Others

5. Interventional Cardiology And Peripheral Vascular Devices Market, By Application

• Coronary Artery Disease
• Peripheral Artery Disease
• Others

6. Interventional Cardiology And Peripheral Vascular Devices Market, By End-User

• Hospitals
• Ambulatory Surgical Centers
• Others

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Abbott Laboratories
• B. Braun Melsungen AG
• Biotronik SE & Co. KG
• Boston Scientific Corporation
• C.R. Bard (BD)
• Cardinal Health Inc.
• Cook Medical
• Koninklijke Philips N.V.
• Medtronic plc
• Teleflex Inc.
• Terumo Group
• W. L. Gore & Associates Inc.

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References